Davidson Kempner Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Davidson Kempner Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-407,871	Closed	-$72.5M	–	539
2021 Q2	$72.5M	Buy	407,871 +21,075	+5%	+$3.65M	0.56%	35
2021 Q1	$63.6M	Sell	386,796 -76,407	-16%	-$12.6M	0.63%	39
2020 Q4	$76.5M	Sell	463,203 -450,988	-49%	-$67.2M	0.9%	27
2020 Q3	$130M	Buy	914,191 +445,161	+95%	+$55.2M	1.85%	11
2020 Q2	$51.7M	Buy	+469,030	New	+$51.9M	1.25%	14

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Davidson Kempner Capital Management's JAZZ Position: Q3 2021 in Review

Davidson Kempner Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 407,871 shares — an estimated $72.5M sold.

Davidson Kempner Capital Management first reported a position in JAZZ in Q2 2020 and held it in 5 quarters. The position peaked at $130M in Q3 2020. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Davidson Kempner Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Davidson Kempner Capital Management sold 407,871 Jazz Pharmaceuticals shares in Q3 2021, an estimated $72.5M.
Davidson Kempner Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2020 and held it in 5 quarters.
Davidson Kempner Capital Management's Jazz Pharmaceuticals position peaked at $130M in Q3 2020.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Davidson Kempner Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.